German Tech Holding considers entry into the biotech sector
Frankfurt-based German Tech Holding GmbH & Co. KGaA (GTH) has announced plans for a potential new investment. The company, which has operated as a holding company since its founding in 2012, is currently exploring a possible stake in a young biotech startup.
The focus of the review is an innovative project in the field of radiopharmacy. The startup is working on a so-called disruptive radiopharmaceutical specifically developed for modern cancer diagnostics. Such technologies are intended to help detect cancer more precisely and at an earlier stage.
For German Tech Holding, this step represents a potential expansion of its portfolio. To date, the holding company has focused on various technological investments. An interest in a biotech company would be a strategic move into the field of medical research, which is considered to have a promising future.
Whether a collaboration will actually come to fruition remains open at this time. According to the company, GTH is still in the evaluation phase to accurately assess the startup's economic and technological opportunities. Further details regarding the potential investment have not yet been released.